Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

31 Mar 2021

Destiny Pharma - Phase 2b study results - Investor Presentation video - 30 March 2021

Watch CEO Neil Clark and CFO Shaun Claydon discuss the 'outstanding' outcome of the trial for XF-73, their nasal gel in development to prevent post-surgical infection.

They also address multiple diverse questions from the investors' audience, and the video lasts 37 minutes in total.

See it here:

Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 2nd Floor, Park House, 16-18 Finsbury Circus, London, EC2M 7EB

Website design & development by Breckenridge